Skip to main content

Table 4 Prevalence (%) of patients experiencing ≥1 exacerbation and health services utilization among COPD patients in the commercial and Medicare datasets*

From: Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data

Parameter, Commercial dataset
(n = 42,565)
Medicare dataset
(n = 8,507)
Exacerbations   
   Inpatient hospitalization 13.9 19.4
   ER visit exacerbation 4.5 4.5
   Ambulatory exacerbations, with qualifying diagnosis 35.6 27.6
   Ambulatory exacerbations supported by qualifying drug therapy 49.6 34.0
   Total exacerbations (any of the above types) 70.6 61.0
Health services   
   Hospitalization (any reason) 39.2 52.9
   Office consultation/visit 98.7 96.4
   Standard chest X-rays 73.1 74.8
   Electrocardiogram 56.9 68.9
   Pulmonary function testing 40.0 33.2
   Respiratory-related equipment/supplies 26.0 35.7
   Heart echo exam 25.8 40.1
   Chest/thorax CT/MRI 23.6 26.6
   Cardiovascular stress test 19.2 19.2
   Respiratory/inhalation therapy 19.1 14.9
   Cardiac catheterization/coronary angiography 9.3 8.0
   Bone density study 7.8 7.6
   Sleep studies 5.4 2.0
   Disease management program 4.1 0
   Bronchoscopy 3.9 3.6
  1. *All of the differences comparing prevalence of comorbid conditions between commercial and Medicare populations were significant (p < 0.01), using two-tailed, chi-squared analysis, except for those indicated by italic text.